Thalassemia is a congenital hemolytic disorder caused by a partial or complete deficiency of α- or β-globin chain synthesis. Homozygous carriers of β-globin gene defects suffer from severe anemia and other serious complications from early childhood. The disease is treated by chronic blood transfusion. However, this can cause severe iron overload resulting in progressive organ failure. Some forms of α thalassemia are also associated with a similar clinical picture. Despite the difficulties associated with treatment, standards of care for thalassemic patients have improved in recent years, resulting in almost doubling of the average life expectancy. As a consequence, additional previously undescribed, complications are now being recognized. In particular, profound hemostatic changes have been observed in patients with β-thalassemia major (β-TM) and β-thalassemia intermedia (β-TI) and also in patients with α thalassemia (hemoglobin H disease). The presence of a higher than normal incidence of thromboembolic events, mainly in β-TI, and the existence of prothrombotic hemostatic anomalies in the majority of the patients, even from a very young age, have led to the recognition of the existence of a chronic hypercoagulable state in thalassemic patients. Despite the appearance of numerous publications on the frequent occurrence of thromboembolic complications in thalassemia, this complication has not been emphasized or comprehensively reviewed. This review summarizes the current literature and discusses possible mechanisms of the lifelong hypercoagulable state that exists in thalassemia.

Cerebral thrombosis

There have been numerous reports of thromboembolic complications associated with thalassemia, many describing cerebral thrombotic events. As early as 1972, Logothetis et al,6 reviewing 138 cases of β-thalassemia major (β-TM) in Greece, described a “stroke syndrome” in 2 patients and neurologic deficits compatible with transient ischemic attacks in about 20% of the cases. An Italian multicenter study of 735 patients with β-TM reported 16 individuals with cerebral thromboembolic events accompanied by a clinical picture of headache, seizures, and hemiparesis.7 Cerebral thrombosis was also found in patients with β thalassemia/hemoglobin E disease and in α thalassemia.8,9 All these reports were from patients who were not given regular transfusions and were not associated with an individual blood transfusion. Other reports have described cases of hypertension, convulsion, and cerebral hemorrhage in thalassemic patients following blood transfusion.10-13 Asymptomatic brain damage has also been reported; results from magnetic resonance imaging (MRI) on 41 patients with β-thalassemia intermedia (β-TI) revealed asymptomatic brain damage including ischemic lesions as a frequent occurrence affecting 37% of patients.14Damage was inversely correlated with hemoglobin levels in patients with β-TI and increased with age.

Deep venous thrombosis and pulmonary embolism

Deep venous thrombosis (DVT), pulmonary embolism, and recurrent arterial occlusion have been described in patients with β-TM and β-TI from many countries.9,15-19 In most cases, thrombosis was spontaneous and there were no known risk factors, although some patients with thrombocytosis after splenectomy developed venous thrombosis. Following these sporadic reports, several multicenter studies were carried out to determine the incidence of thromboembolism in patients with β-TM and β-TI. In one Italian multicenter study, 32 of 735 patients (4.35%) experienced thromboembolic events. The incidence was 3.95% among 685 β-TM patients and 9.61% among 52 patients with β-TI.7 The same group reported a lower incidence (1.1%) of thromboembolic complications among 1146 patients with β-TM who were followed for 37 years.7 Another study showed a 5.3% overall incidence of thrombotic complications among 495 patients with thalassemia whose median age was 28 years.1,2 In this study, the prevalence of thromboembolic events was 3.3% among 421 patients with β-TM and 16.2% among 74 patients with β-TI, although 15.3% of these patients had predisposing congenital or acquired factors contributing to the hypercoagulability.2 Recently, Cappellini et al19 observed a high incidence of venous thromboembolic events (VTEs) in a group of 83 patients with β-TI who were followed for 10 years. Twenty-four patients (29%) developed either pulmonary embolism, DVT, or portal vein thrombosis, and recurrent VTEs occurred in 9 of these cases. All patients except one had undergone splenectomy.

Autopsy findings in patients with thalassemia have clearly demonstrated hypercoagulability as a pathologic feature.20,21 Autopsies on 17 splenectomized and 2 nonsplenectomized patients of 43 with β thalassemia/hemoglobin E disease showed atherosclerotic changes and obstructive lesions consisting of organized, recanalized thrombi in the pulmonary arteries and microvasculature. No evidence of thromboembolism was found elsewhere, although routine dissection of the veins in the legs was not performed.20 Similar findings of multiple microthrombi in the pulmonary arterioles, composed mainly of platelets, were found in autopsies performed on 2 thalassemic patients.21 Asymptomatic pulmonary vascular disease that could result from silent, recurrent thromboembolic events has been found in many patients with β-TM and β-TI. This was suggested by echocardiographic studies in 35 β-TM patients who had no clinical signs or symptoms of thromboembolic disease. Many of the patients showed pulmonary hypertension and right heart failure, which were more prevalent than left heart failure.22 In addition, reduced lung volumes and flow rates, hypoxemia, reduced carbon monoxide diffusion in the lung (DLCO), and pulmonary hypertension were found in these patients.22 In another study of 15 thalassemic patients, the mean total lung capacity, mean residual volume, and mean forced vital capacity were significantly reduced.23 In addition, the DLCO was low, and hypoxemia was present in 6 of 13 patients tested.23 These findings suggest that the early right ventricular dysfunction, which precedes left heart failure in many patients with β-TM and β-TI, may be due to pulmonary hypertension and not cardiomyopathy resulting from excessive iron deposition.24,25 In support of this idea, a Doppler echocardiography study in which pulmonary artery pressure was measured in 33 patients with β-TM (aged 2-24 years) showed that 28 patients had evidence of pulmonary hypertension.26 Pulmonary artery hypertension was also detected by M-mode and Doppler echocardiography in 15 of 16 children, aged 5 to 14 years, with homozygous β thalassemia and β thalassemia/hemoglobin E disease.27Right ventricular dysfunction was detected earlier than left ventricular dysfunction in these children, suggesting that the right heart failure and pulmonary hypertension seen in thalassemia could result from microembolization in the lungs. Indeed, autopsy findings revealed a high frequency of thrombotic lesions in the pulmonary arteries and the development of cor pulmonale consistent with a long-standing pulmonary vascular embarrassment.20,21 The venous and arterial thrombotic events have not received much attention and were not mentioned in comprehensive reviews on thalassemia.5 

Platelet activation

In 1978, Eldor28 and a year later Houssain et al29 found defective platelet aggregation in response to adenosine diphosphate, epinephrine, or collagen in β-TM patients. Most of the patients had undergone splenectomy and had high platelet counts. At that time, these anomalies were interpreted as signs of a mild bleeding disorder because many thalassemic patients experience frequent epistaxis as well as easy bruising.28 However, in 1981 Winichagoon et al30 found increased circulating platelet aggregates in 71% of splenectomized and 35% of nonsplenectomized patients with β-TI/hemoglobin E disease, an observation compatible with in vivo platelet activation and the existence of a hypercoagulable state. Supporting evidence for this finding came from platelet kinetic studies in β-TM and β-TI patients using autologous platelets labeled with indium In 111 oxine.31 A significant shortening of platelet life span was observed in 13 of 14 patients examined. The mean platelet life span in 10 patients (8 β-TM and 2 β-TI) who underwent splenectomy was 107 ± 36 hours compared to 248 ± 51 hours in healthy individuals who underwent splenectomy because of trauma (P < .001). The mean platelet life span in 4 nonsplenectomized patients (2 β-TM and 2 β-TI) was 102 ± 64 hours compared to 224 ± 23 hours in healthy individuals (P < .01). Analysis of the data suggested that the shortened platelet life span was caused by enhanced platelet consumption,31 a feature usually associated with active thrombotic disease, severe atherosclerosis, diabetes mellitus, and other chronic hypercoagulable states.

Further evidence for the existence of chronic platelet activation in thalassemia was provided by the measurement of urinary metabolites of thromboxane A2 (TXA2) and prostacyclin (PGI2). A study of 9 splenectomized patients with β-TM who were regularly transfused, 5 nonsplenectomized patients with β-TI who received occasional blood transfusions, and 20 healthy individuals3,32 found a significant 4- to 10-fold increase in the urinary excretion of 2,3-dinor-TXB2, 11-dehydro-TXB2, and 2,3-dinor-6-keto-prostaglandin (PG) F in patients with β-TM and β-TI compared to healthy controls. The concentration of metabolites in patients with β-TM and β-TI was not significantly different, and 6 patients who received aspirin (20 mg/d) for 7 days showed a significant decrease in their urinary concentrations of 2,3-dinor-TXB2 and 11-dehydro-TXB2 derived from platelets. In contrast, levels of urinary 2,3-dinor-6-keto-PGF, reflecting vascular production, and TXB2 and 6-keto-PGForiginating from the kidney were not significantly changed.32 The results of this study are consistent with enhanced production of TXA2 due to chronic endogenous platelet activation and reflect the increased concentrations of urinary thromboxane metabolites found in other diseases associated with in vivo platelet activation including unstable coronary disease, severe atherosclerosis, and type II diabetes mellitus.33-36 In another more recent study,4 urinary prostaglandin metabolites were determined in a group of 62 β-TM patients comprising 26 children (aged 2-18) and 36 adults. All the thalassemic children (including the youngest, aged 2-8 years) and the adults had highly elevated levels of the urinary prostaglandin metabolites, 11-dehydro-TXB2 and 2,3-dinor-6-keto-PGF. None of the thalassemic children had experienced clinical signs or symptoms suggestive of venous or arterial thrombosis, indicating that platelet activation in thalassemic patients persists from early in childhood when clinical thrombotic events are extremely rare.

The existence of chronic platelet activation in thalassemia was further confirmed by flow cytometric studies, which demonstrated the presence of an increased fraction of platelets carrying the activation markers CD62P (P selectin) and CD63.37,38 In addition, morphologic changes in thalassemic platelets, elevated plasma platelet factor 3 (PF3), and increased spontaneous whole blood platelet aggregation were reported.39-41 

The results from these studies show that, in addition to their increased number in splenectomized patients, chronic platelet activation is present in β-TM and β-TI. This may explain the weak response of thalassemic platelets to aggregation agonists reported previously28 as the activated platelets become refractory to additional stimulation.32 The presence of morphologic platelet abnormalities in splenectomized patients with β thalassemia/hemoglobin E disease may also contribute to an enhanced risk of vascular complications.42 

Endothelial, monocyte, and granulocyte activation

The detection of elevated levels of endothelial adhesion proteins (intercellular adhesion molecule-1 [ICAM-1], E-selectin [ELAM-1], vascular cell adhesion molecule-1 [VCAM-1], von Willebrand factor [VWF], and thrombomodulin) in serum and plasma of thalassemic patients suggested that endothelial activation or injury may be a feature of the disorder.43,44 The adherence of red blood cells (RBCs) to endothelial cells (ECs) correlates with microvascular occlusions in sickle cell disease (SCD) and malaria and is considered a major contributor to microcirculatory disorders.45 RBCs from patients with β-TM and β-TI showed enhanced adhesion to cultured ECs (10- to 25-fold increase compared to normal RBCs).46 Similar findings were described in SCD45,47 where the interaction of sickle RBCs with ECs induced a state of oxidative stress leading to enhanced transendothelial migration of blood monocytes.48 

Monocyte activation may also play a significant role in heightening endothelial activation or injury in both thalassemia and SCD. High serum levels of monocyte colony-stimulating factor and increased monocyte phagocytic activities (antibody-dependent cell cytotoxicity [ADCC]) toward RBCs were found in patients with hemoglobin H disease and β-TM.49 Recently, it was shown that ECs incubated with sickle mononuclear leukocytes were activated to a greater extent than those incubated with normal mononuclear leukocytes, as judged by the increased endothelial expression of adhesion molecules and tissue factor and the adhesion of polymorphonuclear leukocytes.50 Sickle monocytes, which had 34% more interleukin 1β and 139% more tumor necrosis factor-α per cell than normal monocytes, caused the nuclear translocation of endothelial nuclear factor κ B, an event indicating EC activation.50It is possible that a similar mechanism may operate in thalassemia.

Activated granulocytes could also contribute to the endothelial damage and the hypercoagulable state in thalassemia. Elevated granulocyte phagocytic function, as manifested by enhanced chemiluminescence, was observed in patients with β-TM, with greater prominence of the abnormality in patients older than 5 years.51 Removal of leukocytes from transfused blood with a Leukostop filter resulted in improved pulmonary function tests (forced expiratory volume in 1 second/forced vital capacity ratio) in 4 patients with β-TM, 6 months after the procedure.52 This clinical observation illustrates the deleterious effect that activated granulocytes can induce in the lungs of patients with thalassemia.

Studies of the coagulation proteins provide strong evidence for the existence of a chronic hypercoagulable state in thalassemia. Several investigators have reported profound changes in the levels of coagulation factors, coagulation factor inhibitors, and components of the fibrinolytic system.

In a study by Eldor et al,4 plasma prothrombin levels were significantly lower in adult patients (aged 19-30 years) with β-TM (68% ± 11.5%) compared to age-matched healthy controls (86.1% ± 12.3%), whereas the levels of factors V, VII, X, and plasminogen were similar. Similarly reduced levels of prothrombin (61.1% ± 6.5%) were observed in a group of children, aged 2 to 18 years, with β-TM, suggesting that this anomaly is related to the thalassemia rather than to hepatic dysfunction due to hemosiderosis, which is a rare occurrence in children.4 

Low levels of the coagulation inhibitors, protein C and protein S, have been observed in patients with β thalassemia from a variety of ethnic backgrounds.4,19,53,54 In Israeli patients mostly of Kurdish Jewish, Yemenite Jewish, or Arabic origin, protein C (antigen and activity) and free protein S were significantly decreased in both adults and children.4 Mean protein C antigen levels were 51.2% ± 11.2% in adult β-TM patients and 46% ± 9.1% in β-TM children (aged 2-13 years); they were 94.1% ± 21% in healthy individuals (P < .001). Similar values were obtained for protein C activity: 52.3% ± 12.1% in β-TM adults, 48.8% ± 14.7% in β-TM children, and 99.2% ± 16.1% in healthy controls (P < .001). Levels of free protein S were 49.3% ± 9.6% in β-TM adults, 43.4% ± 8.7% in β-TM children, and 85.1% ± 18.2% in the control group (P < .001). The decreased levels of free protein S were not due to low C4b-binding protein levels that were similar in β-TM patients and the controls.4 No correlation was found between the levels of protein C and protein S and the levels of prothrombin or any other coagulation factors. Furthermore, protein C and protein S levels in β-TM patients were not related to levels of serum transaminases, γ-glutamyl transferase, or albumin, eliminating hepatic dysfunction as a cause of these anomalies.4Similar results were obtained in studies of β-TI patients in Italy19 and patients with α- or β-TM in Thailand and Turkey.53,54 Some thalassemic patients from Italy and Turkey had low antithrombin III (ATIII) levels in addition to protein C and protein S deficiencies, whereas no ATIII deficiency was found in the Israeli patients.4,19 55 

Low levels of heparin cofactor II (HCII), known to be associated with increased thrombotic risk, have been found in thalassemic patients.56 Frequent blood transfusions resulted in a slow normalization of HCII levels, suggesting that the low HCII levels could be related to increased RBC turnover that had been suppressed by hypertransfusion.56 

The possibility of a genetic basis for the hypercoagulable state in thalassemic patients seems unlikely because a study of 25 Israeli β-TM patients (18 adults, 7 children) found no increased prevalence of congenital thrombophilic mutations, including the factor V Leiden, MTHFR C677T, and prothrombin G20210A mutations. In addition, none of the patients showed evidence of anticardiolipin antibody.4 

In conclusion, it seems that the low levels of protein C and free protein S seen in thalassemic patients may be acquired at an early age. The extent to which the imbalance between coagulation inhibitors and clotting factors contributes to the hypercoagulable state in thalassemia remains to be determined.

The existence of a chronic and lifelong hypercoagulable state in thalassemia was further supported by the elevated levels of thrombin-ATIII (TAT) complexes found in about 50% of adults and children with β-TM.4 Increased TAT levels were detected on repeated examinations in many of the patients, of whom none had any clinical signs of overt thrombosis. In this group of patients the levels of the prothrombin fragment, F1.2, were normal.4 However, significantly elevated levels of F1.2 and fibrinopeptide A (FPA) were found in splenectomized patients with β-TI, and these patients also had high plasma D-dimer levels, a manifestation of enhanced fibrinolysis.19 Elevated TAT levels were also observed in patients with α thalassemia (unpublished results, January 2001).

The mechanism of the hypercoagulable state in thalassemia has not been fully elucidated. However, evidence from studies of other types of hemolytic anemia, such as SCD and paroxysmal nocturnal hemoglobinuria (PNH), in which thrombosis is also a major clinical entity, may be helpful in understanding the etiology of the latter phenomena.57-59 

A comparison of normal RBCs with those isolated from patients with β-TM or β-TI by our group suggests that thalassemic RBCs may provide a source of negatively charged phospholipids, which can increase thrombin generation, as measured by prothrombinase assay.60,61 These results were confirmed in a similar assay using RBCs from splenectomized β-TI patients as a source of phospholipids.19 The procoagulant effect of thalassemic RBCs seems to be due to an increased surface expression of anionic phospholipids such as phosphatidylethanolamine (PE) and phosphatidylserine (PS). This was demonstrated by experiments that showed that annexin V, which binds anionic phospholipids, could block the procoagulant effect of isolated thalassemic RBCs.61These data suggest that the procoagulant effect of thalassemic RBCs may contribute to the hypercoagulable state in thalassemia by amplifying thrombin generation and initiating platelet activation.

To substantiate these findings, we measured the ability of RBCs from thalassemia patients to bind annexin V using dual-color flow cytometry.38 Significantly higher (P < .01) fractions of fluorescein isothiocyanate (FITC)–annexin V–labeled RBCs were found in 30 β-TM patients (2.9% ± 1.9%; range, 0.5%-7.5%) and 6 β-TI patients (2.5% ± 2.8%; range, 0.9%-6.9%) compared to 25 healthy individuals (0.5% ± 0.3%; range, 0.1%-1.2%). Results of tests on patients with myelodysplastic syndrome and severe anemia were similar to those observed for a healthy control group.38 Moreover, in the thalassemic patients, a highly significant correlation (P < .001) was found between the number of RBC-bound annexin V molecules and the fraction of CD62P (P selectin) or CD63+ platelets.38 This association between annexin V binding and the expression of platelet activation markers was also found in individual thalassemic patients over time and was not dependent on whether the patients had undergone splenectomy. These results support the idea that the procoagulant surface of thalassemic RBCs promotes thrombin generation in vivo leading to platelet activation.38 

The asymmetrical distribution of membrane phospholipids seen in normal RBCs seems to be the result of a direct interaction of PS and PE with membrane skeletal proteins (mostly spectrin) and an adenosine triphosphate (ATP)–dependent unidirectional translocation of PS and PE from the outer toward the inner membrane leaflet (Figure1).62-65 This reaction is catalyzed by the aminophospholipid translocase enzyme that recognizes both PS and PE.63,64 Aged RBCs contain higher amounts of PS on the outer leaflet of their membranes compared to young cells and this may serve as a signal for their recognition and removal by the reticuloendothelial system.65 Deoxygenated (sickled) RBCs from patients with SCD show an abnormal distribution of membrane phospholipids that is caused by an accelerated trans-bilayer diffusion of phosphatidyl choline (PC) and a reduced rate of ATP-dependent transport of PS and PE.57,58 The existence of such membrane phospholipid asymmetry in the RBCs of patients with thalassemia was recently demonstrated.66 The membrane damage in thalassemic RBCs may be related to the primary abnormality in RBC lipids caused by lipid membrane peroxidation mediated by free iron.67 In fact, increased amounts of membrane-bound hemichromes and immunoglobulins were found in the RBCs of β-TM and β-TI patients and the membrane band 3 protein showed oxidative modifications such as aggregation and a decrease in sulfhydryl groups.68,69 The membrane phospholipid abnormalities in thalassemic and sickle RBCs may partly explain the increased adherence of PS-exposing RBCs to ECs (Figure 1). When human umbilical vein endothelial cell monolayers were incubated with PS-exposing RBCs, the ECs retracted and the RBCs adhered primarily in the gaps that had been opened between the ECs. Pretreatment of RBCs with annexin V significantly reduced adherence by shielding PS on the RBCs. This suggests an important contribution of the PS-exposing RBCs to the vascular damage observed in thalassemia and sickle cell anemia.45 

Fig. 1.

The hypercoagulable state in thalassemia.

Thalassemia is associated with partial or complete deficiency of α- or β-globin chain synthesis, which leads to denaturation and degradation of the remaining globin chains. This process is associated with loss of the normal asymmetrical distribution of the RBC membrane phospholipids and translocation of PS to the external membrane leaflet (flip-flop). The membrane damage may be related to lipid peroxidation mediated by free iron and increased amounts of membrane-bound hemichromes and immunoglobulins and modifications in the membrane band 3 protein and spectrin. The membrane changes may partly explain the enhanced aggregation of PS-exposing RBCs, their increased adherence to ECs, and their capacity to enhance thrombin generation via the assembly of the prothrombinase complex. The enhanced thrombin generation leads to activation of platelets, monocytes, granulocytes, and ECs and expression of tissue factor, which further enhances the thrombotic process. The low levels of the coagulation inhibitors, protein C and protein S, further facilitate the resultant hypercoagulable state.

Fig. 1.

The hypercoagulable state in thalassemia.

Thalassemia is associated with partial or complete deficiency of α- or β-globin chain synthesis, which leads to denaturation and degradation of the remaining globin chains. This process is associated with loss of the normal asymmetrical distribution of the RBC membrane phospholipids and translocation of PS to the external membrane leaflet (flip-flop). The membrane damage may be related to lipid peroxidation mediated by free iron and increased amounts of membrane-bound hemichromes and immunoglobulins and modifications in the membrane band 3 protein and spectrin. The membrane changes may partly explain the enhanced aggregation of PS-exposing RBCs, their increased adherence to ECs, and their capacity to enhance thrombin generation via the assembly of the prothrombinase complex. The enhanced thrombin generation leads to activation of platelets, monocytes, granulocytes, and ECs and expression of tissue factor, which further enhances the thrombotic process. The low levels of the coagulation inhibitors, protein C and protein S, further facilitate the resultant hypercoagulable state.

Close modal

Several studies have suggested that RBCs from thalassemic patients also demonstrate enhanced cohesiveness, which may contribute to the hypercoagulable state. Using a novel image analysis system to measure RBC aggregation in a flow chamber, an increased cohesion of TM RBCs was detected, demonstrated by the formation of large aggregates.70 Normal rouleaux formation was absent and higher shear stress was required to disperse the aggregates. It is noteworthy that RBC aggregate size was reduced to normal after patients received a blood transfusion and this observation was confirmed by in vitro experiments where the addition of normal RBCs to thalassemic RBCs resulted in reduced aggregation under flow.70 These in vitro findings could partly explain the recent clinical observation that patients with β-TI who do not receive transfusions regularly had a much higher incidence of thrombotic events compared to the incidence of such events in those receiving regular transfusions.19 

The contribution of the abnormal RBCs to the thrombotic process has been also demonstrated in animal models of congenital hemolytic anemias.71-74 A lethal hypercoagulable state manifested by large thrombotic lesions in the heart and the liver and large venous thrombi was found in mice in which the expression of erythroid band 3 had been eliminated via targeted mutagenesis.71 The abnormal RBCs from these mice significantly shortened the Russell viper venom clotting time of normal plasma in a dose-dependent fashion, whereas RBCs from normal mice had no effect. These experiments suggested that the membrane of band 3 null RBCs provides a suitable surface for activation of the prothrombinase complex and, indeed, PS exposure on the outer membrane leaflet of the affected RBCs was demonstrated by increased FITC-annexin V binding.71 A high incidence of thrombosis in the heart and brain was also found in α-spectrin– and β-spectrin–deficient mice with hereditary spherocytosis.72 Thrombosis incidence in these animals was significantly reduced following the transfusion of normal RBCs or transplantation of normal bone marrow.73 The presence of normal RBCs in the peripheral circulation of these α-spectrin–deficient mice prolonged the survival of young animals and abrogated the development of thrombosis in adult animals.73 

Similar thrombotic complications and hemostatic abnormalities, characteristic of a chronic hypercoagulable state, have been described in SCD (Table 1). Although much of the morbidity in SCD is caused by tissue ischemia and infarction (sickle cell crisis) resulting from microvascular occlusions caused by the abnormal sickling RBCs, these events are not associated with an activation of the hemostatic system.74-76 However, both adults and children with SCD are known to have an ill-defined but increased thrombotic risk associated with large blood vessels.76 Stroke occurs in 7% to 8% of children with SCD (hemoglobin SS) and is a major cause of morbidity.77-79 Silent brain lesions revealed by MRI are common and are associated with impairments of cognitive function.80,81 Sporadic cases of DVT, pulmonary embolism, portal vein thrombosis, aseptic necrosis of bone, leg ulcers, retinopathy, and miscarriage have also been reported.82-86Hemostatic abnormalities, including low protein C and protein S levels, and elevated plasma concentrations of TAT, F1,2, and D-dimer complexes have been found in sickle cell patients.61,75,87-89 In addition, chronic platelet activation was indicated by the elevated plasma levels of platelet factor 4 (PF4) and β-thromboglobulin (β-TG) and the expression of P selectin and enhanced binding of annexin V to the SCD platelets.89 These markers of platelet activation, thrombin generation, and enhanced fibrinolyisis were significantly elevated in asymptomatic subjects with SCD and further increased during episodes of pain.89 

Table 1.

Hemostatic parameters in thalassemia and SCD

Assayβ-TMβ-TIα-ThalassemiaSCD
Platelet Life span Short Short   
 Aggregation Impaired Impaired  Impaired 
 Urinary TXA2 High High  High 
 Circulating platelet aggregates Present Present Present Present  
 CD62, CD63 High High  High 
 PF3 High High High  
 PF4, β-TG High High  High  
Vascular endothelium Thrombomodulin High High  High 
 ICAM-1 High High  High 
 VCAM-1 High High  High 
 VWF High High  High 
 E-selectin High High  High  
 Urinary PGI2 High High  High  
RBC Annexin V binding Increased Increased  Increased  
 Thrombin generation Increased Increased  Increased  
Coagulation factors Factor II Low Low   
 Factors V, VII, X Normal Normal   
Coagulation inhibitors Protein C (antigen, activity) Low Low  Low  
 Protein S (free) Low Low  Low 
 ATIII Normal Low  Normal 
 HCII Low    
Thrombin generation TAT High High High High 
 F1,2 Normal High  Normal 
 FPA  High  High 
 D-dimer  High  High 
Assayβ-TMβ-TIα-ThalassemiaSCD
Platelet Life span Short Short   
 Aggregation Impaired Impaired  Impaired 
 Urinary TXA2 High High  High 
 Circulating platelet aggregates Present Present Present Present  
 CD62, CD63 High High  High 
 PF3 High High High  
 PF4, β-TG High High  High  
Vascular endothelium Thrombomodulin High High  High 
 ICAM-1 High High  High 
 VCAM-1 High High  High 
 VWF High High  High 
 E-selectin High High  High  
 Urinary PGI2 High High  High  
RBC Annexin V binding Increased Increased  Increased  
 Thrombin generation Increased Increased  Increased  
Coagulation factors Factor II Low Low   
 Factors V, VII, X Normal Normal   
Coagulation inhibitors Protein C (antigen, activity) Low Low  Low  
 Protein S (free) Low Low  Low 
 ATIII Normal Low  Normal 
 HCII Low    
Thrombin generation TAT High High High High 
 F1,2 Normal High  Normal 
 FPA  High  High 
 D-dimer  High  High 

The various assays are detailed in the text.

Evidence for endothelial activation in SCD was provided by the elevated urinary levels of 11-dehydro-TXB2 and the 2,3-dinor-6-PGF74 and increased numbers of circulating microvascular endothelial cells (CD36+) overexpressing ICAM-1, VCAM-1, E selectin, P selectin, and tissue factor found in these patients.89-91 Sickle RBCs expressing anionic phospholipid surfaces, manifested by enhanced annexin V binding, have been shown to have a procoagulant effect and are thought to be significant in the pathogenesis of the thrombotic manifestations.57,58,61,90 In support of this idea, significant reductions in the rates of stroke recurrence in sickle cell patients from 46% to 90% to less than 10% have been achieved by chronic blood transfusions and maintenance of hemoglobin S levels at less than 30%.92,93 Transfusion has also been shown to greatly reduce the risk of a first stroke in children with SCD who have abnormal results on transcranial Doppler ultrasonography.94 

Thrombotic manifestations were also observed in 2 knockout-transgenic mouse models of SCD.95,96 These animals, which had exclusively human sickle hemoglobin, showed all the major features of human SCD, including thrombotic infarcts and vascular occlusions in the spleen, liver, and kidneys, and these thrombotic events were already observed at a relatively young age.95 96 

Other congenital hemolytic anemias also carry an increased risk for thromboembolic events.59 PNH is reported to be associated with an increased tendency for DVT and portal vein thrombosis,97,98 and frequent thrombotic episodes were reported in 9 patients with hereditary stomatocytosis. Data on abnormal hemostatic parameters in these disorders are currently not available.99 

A range of laboratory tests has provided solid evidence for the existence of a chronic hypercoagulable state in thalassemia and, particularly, in splenectomized patients with β-TI who do receive regular transfusions. Thalassemic patients have low levels of protein C and protein S, show enhanced platelet consumption, and show ongoing platelet, monocyte, granulocyte, and endothelial activation. Increased plasma levels of activation peptides, TAT, F1,2, FPA, and D-dimer, are suggestive of continuous thrombin generation and enhanced fibrinolysis.

Thrombosis is typically an episodic complication associated with a temporary activation of hemostasis. In contrast, markers of platelet and coagulation activation are persistently and consistently elevated in most thalassemic patients (adults and children alike), even in the absence of overt thromboembolic events.4 The presence of a persistent hypercoagulable state combined with the infrequent occurrence of significant thrombotic events suggests that thrombosis is largely a subclinical process in thalassemia and has been associated with autopsy findings of platelet and fibrin thrombi in the microvasculature in the lungs and the brain.20,21 These thrombi could contribute to the pulmonary hypertension, low lung capacity, hypoxemia, and diffusion defects associated with right heart failure (cor pulmonale)22-27 and to the high frequency of ischemic brain lesions associated with asymptomatic brain damage as detected by MRI.14 

Several etiologic factors may play a role in the pathogenesis of the hypercoagulable state in thalassemia. The specific changes in the lipid membrane composition of the abnormal RBCs and the hemosiderosis may contribute to the activation of the coagulation process and the activation of other blood cells, including the platelets, monocytes, and granulocytes, alone or together, and may induce activation of the vascular endothelium, which further contributes to the thrombotic process. The exact order of these events is still unclear, and the murine models of congenital hemolytic anemias may shed some light on the role of these anomalies in the induction of the hypercoagulable state.71-73 

Venous thrombosis is more prevalent in β-TI patients who are not receiving regular transfusions and who have undergone splenectomy. These patients may be more susceptible to thromboembolism because they have more circulating damaged RBCs and increased platelet counts. The beneficial role of regular blood transfusions is illustrated by the observation that thromboembolic manifestations are more frequently recorded in less developed countries with limited transfusion resources and ex vivo and in vitro experiments that show that normal RBCs can eliminate the abnormal aggregation observed with thalassemic RBCs.70 

The addition of prophylactic antithrombotic therapy has only recently been suggested for high-risk patients with β-TI who are exposed to transient thrombotic risk factors (eg, surgery, immobilization, pregnancy).19 Thalassemia major patients who had developed an acute thrombotic event should be considered for prolonged antithrombotic therapy, as for any patients with thrombophilia, in view of their profound hemostatic anomalies. What remains to be seen is whether lifelong treatment with antithrombotic agents is indicated in patients with thalassemia to prevent any subclinical thrombosis in the lungs and brain. It is noteworthy that some thalassemic patients responded to treatment with platelet inhibitor drugs (aspirin and dipyridamole) with a rise in their arterial oxygen content.21 

Dr Amiram Eldor tragically passed away on Saturday, November 24, 2001, returning home from a scientific meeting in Germany; his many contributions to hematology will be remembered, and his presence in our community will be greatly missed.—Ed

Amiram Eldor died on November 24, 2001.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Borgna-Pignatti
C
Rugolotto
S
De Stefano
P
et al
Survival and disease complications in thalassemia major.
Ann N Y Acad Sci.
850
1998
227
231
2
Moratelli
S
De Sanctis
V
Gemmati
D
et al
Thrombotic risk in thalassemic patients.
J Pediatr Endocrinol Metab.
11
1998
915
921
3
Eldor
A
Maclouf
J
Lellouche
F
et al
A chronic hypercoagulable state and life-long platelet activation in beta thalassemia major.
Southeast Asian J Trop Med Public Health.
24
1993
92
95
4
Eldor
A
Durst
R
Hy-Am
E
et al
A chronic hypercoagulable state in patients with beta-thalassemia major is already present in childhood.
Br J Haematol.
107
1999
739
746
5
Olivieri
NF
The β-thalassemias.
N Engl J Med.
341
1999
99
109
6
Logothetis
J
Constantoulakis
M
Economidou
J
et al
Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects.
Neurology.
22
1972
294
304
7
Borgna Pignatti
C
Carnelli
V
Caruso
V
et al
Thromboembolic events in beta thalassemia major: an Italian multicenter study.
Acta Haematol.
99
1998
76
79
8
Wong
V
Yu
YL
Liang
RH
Tso
WK
Li
AM
Chan
TK
Cerebral thrombosis in beta-thalassemia/hemoglobin E disease.
Stroke.
21
1990
812
816
9
Tso
SC
Chan
TK
Todd
D
Venous thrombosis in hemoglobin H disease after splenectomy.
Aust N Z J Med.
12
1982
635
638
10
Wasi
P
Na-Nakorn
S
Pootrakul
P
Sonakul
D
Piankijagum
A
Pacharee
P
A syndrome of hypertension, convulsion, and cerebral haemorrhage in thalassemic patients after multiple blood-transfusions.
Lancet.
2
1978
602
604
11
Constantopoulos
A
Matsaniotis
N
Hypertension, convulsion, and cerebral haemorrhage in thalassemic patients after multiple blood transfusions.
Helv Paediatr Acta.
35
1980
269
271
12
Gurgey
A
Kalayci
O
Gumruk
F
Cetin
M
Altay
C
Convulsion after blood transfusion in four beta-thalassemia intermedia patients.
Pediatr Hematol Oncol.
11
1994
549
552
13
Sonakul
D
Fucharoen
S
Brain pathology in 6 fatal cases of post-transfusion hypertension, convulsion and cerebral hemorrhage syndrome.
Southeast Asian J Trop Med Public Health.
23
1992
116
119
14
Manfre
L
Giarratano
E
Maggio
A
Banco
A
Vaccaro
G
Lagalla
R
MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease.
Am J Roentgenol.
173
1999
1477
1480
15
Paolino
E
Monetti
VC
Granieri
E
Boldrini
P
Acute cerebrovascular insults in homozygous beta-thalassemia: a case report.
J Neurol.
230
1983
37
41
16
Michaeli
J
Mittelman
M
Grisaru
D
Rachmilewitz
EA
Thromboembolic complications in beta thalassemia major.
Acta Haematol.
87
1992
71
74
17
Gillis
S
Cappellini
MD
Goldfarb
A
Ciceri
L
Fiorelli
G
Rachmilewitz
EA
Pulmonary thromboembolism in thalassemia intermedia patients.
Haematologica.
84
1999
957
958
18
van Teunenbroek
A
Wijburg
FA
ten Cate
JW
van den Berg
W
Weening
RS
Thromboembolic complications in an asplenic HbE-beta-thalassemia patient.
Neth J Med.
35
1989
123
127
19
Cappellini
MD
Robbiolo
L
Bottasso
BM
Coppola
R
Fiorelli
G
Mannucci
AP
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia.
Br J Haematol.
111
2000
467
473
20
Sonakul
D
Pacharee
P
Laohapand
T
Fucharoen
S
Wasi
P
Pulmonary artery obstruction in thalassemia.
Southeast Asian J Trop Med Public Health.
11
1980
516
523
21
Sumiyoshi
A
Thakerngpol
K
Sonakul
D
Pulmonary microthromboemboli in thalassemic cases.
Southeast Asian J Trop Med Public Health.
23
1992
29
31
22
Grisaru
D
Rachmilewitz
EA
Mosseri
IM
et al
Cardiopulmonary assessment in beta thalassemia major.
Chest.
98
1990
1138
1142
23
Luyt
DK
Richards
GA
Roode
H
Dowdeswell
RJ
van Rensburg
AJ
Reinach
SG
Thalassemia: lung function with reference to iron studies and reactive oxidant status.
Pediatr Hematol Oncol.
10
1993
13
23
24
Grant
GP
Mansell
AL
Graziano
JH
Mellins
RB
The effect of transfusion on lung capacity, diffusing capacity and material oxygen saturation in patients with β-thalassemia major.
Pediatr Res.
20
1986
20
29
25
Koren
A
Garty
I
Antonelli
D
Katzuni
E
Right ventricular cardiac dysfunction in beta-thalassemia major.
Am J Dis Child.
141
1987
93
96
26
Du
ZD
Roguin
N
Milgram
E
Saab
K
Koren
A
Pulmonary hypertension in patients with thalassemia major.
Am Heart J.
134
1997
532
537
27
Chotivittayatarakorn
P
Seksarn
P
Pathmanand
C
Thisyakorn
C
Sueblinvong
V
Cardiac dysfunction in beta-thalassemic children.
J Med Assoc Thai.
76
1993
591
596
28
Eldor
A
Abnormal platelet functions in beta thalassemia.
Scand J Haematol.
20
1978
447
452
29
Houssain
MAM
Hutton
RA
Pavidon
O
Hoffbrand
AV
Platelet function in beta-thalassemia major.
J Clin Pathol.
32
1979
429
433
30
Winichagoon
P
Fucharoen
S
Wasi
P
Increased circulating platelet aggregates in thalassemia.
Southeast Asian J Trop Med Public Health.
12
1981
556
560
31
Eldor
A
Krausz
Y
Atlan
H
et al
Platelet survival in patients with beta-thalassemia.
Am J Hematol.
32
1989
94
99
32
Eldor
A
Lellouche
F
Goldfarb
A
Rachmilewitz
EA
Maclouf
J
In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites.
Blood.
77
1991
1749
1753
33
Davi
G
Catalano
I
Averna
M
et al
Thromboxane biosynthesis and platelet function in type II diabetes mellitus.
N Engl J Med.
322
1990
1769
1774
34
FitzGerald
GA
Smith
B
Pedersen
AK
Brash
AR
Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.
N Engl J Med.
310
1984
1065
1068
35
Fitzgerald
DJ
Catella
F
FitzGerald
GA
Platelet activation in unstable coronary disease.
N Engl J Med.
315
1986
983
989
36
Oates
JA
Branch
A
Jackson
EK
Knapp
HR
Roberts
IJ
Clinical implications of prostaglandin and thromboxane A2 formation.
N Engl J Med.
319
1988
689
698
37
Del Principe
D
Menichelli
A
Di Giulio
S
De Matteis
W
Cianciulli
P
Papa
G
PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassemic patients.
Br J Haematol.
84
1993
111
117
38
Ruf
A
Pick
M
Deutsch
V
et al
In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassemia major.
Br J Haematol.
98
1997
51
56
39
Bunyaratvej
A
Differentiation of platelets from red cell fragments using laser technology: comparison between splenectomized and nonsplenectomized thalassemic patients.
Southeast Asian J Trop Med Public Health.
24
1993
250
252
40
Opartkiattikul
N
Funahara
Y
Fucharoen
S
Talalak
P
Increase in spontaneous platelet aggregation in beta- thalassemia/hemoglobin E disease: a consequence of splenectomy.
Southeast Asian J Trop Med Public Health.
23
1992
36
41
41
Opartkiattikul
N
Funahara
Y
Hijikata-Okunomiya
A
Yamaguchi
N
Fucharoen
S
Talalak
P
Detection of PF3 availability in whole blood from volunteers and beta- thalassemia/HbE patients: a promising method for prediction of thrombotic tendency.
Southeast Asian J Trop Med Public Health.
23
1992
52
59
42
Bunyaratvej
A
Komanasin
N
Sriurairatana
S
Fucharoen
S
Morphological assessment of platelet activation in thalassemia.
Southeast Asian J Trop Med Public Health.
23
1992
60
64
43
Butthep
P
Bunyaratvej
A
Funahara
Y
et al
Alterations in vascular endothelial cell-related plasma proteins in thalassemic patients and their correlation with clinical symptoms.
Thromb Haemost.
74
1995
1045
1049
44
Butthep
P
Bunyaratvej
A
Funahara
Y
et al
Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study.
Southeast Asian J Trop Med Public Health.
28
1997
141
148A
45
Manodori
AB
Barabino
GA
Lubin
BH
Kuypers
FA
Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin.
Blood.
95
2000
1293
1300
46
Hovav
T
Goldfarb
A
Artmann
G
Yedgar
S
Barshtein
G
Enhanced adherence of beta-thalassemic erythrocytes to endothelial cells.
Br J Haematol.
106
1999
178
181
47
Smith
BD
La Celle
PL
Erythrocyte-endothelial cell adherence in sickle cell disorders.
Blood.
68
1986
1050
1054
48
Sultana
C
Shen
Y
Rattan
V
Johnson
C
Kalra
VK
Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes.
Blood.
92
1998
3924
3935
49
Wiener
E
Wanachiwanawin
W
Chinprasertsuk
S
et al
Increased serum levels of macrophage colony-stimulating factor (M-CSF) in alpha- and beta-thalassemia syndromes: correlation with anaemia and monocyte activation.
Eur J Haematol.
57
1996
364
369
50
Belcher
JD
Marker
PH
Weber
JP
Hebbel
RP
Vercellotti
GM
Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion.
Blood.
96
2000
2451
2459
51
Deo
SS
Merchant
SM
Kapadia
AC
Elevated polymorphonuclear phagocytic function in thalassemia patients by chemiluminescence.
Indian J Pediatr.
61
1994
395
399
52
Kivity
S
Gazy
C
Heno
N
Greif
Z
Topilsky
M
Effect of the Leukostop filter on pulmonary function following blood transfusion in patients with thalassemia major.
Pediatr Pulmonol.
28
1999
277
281
53
Visudhiphan
S
Ketsa-Ard
K
Tumliang
S
Piankijagum
A
Significance of blood coagulation and platelet profiles in relation to pulmonary thrombosis in beta-thalassemia/Hb E.
Southeast Asian J Trop Med Public Health.
25
1994
449
456
54
Shirahata
A
Funahara
Y
Opartkiattikul
N
Fucharoen
S
Laosombat
V
Yamada
K
Protein C and protein S deficiency in thalassemic patients.
Southeast Asian J Trop Med Public Health.
23
1992
65
73
55
Musumeci
S
Leonardi
S
Di Dio
R
Fischer
A
Di Costa
G
Protein C and antithrombin III in polytransfused thalassemic patients.
Acta Haematol.
77
1997
30
33
56
O'Driscoll
A
Mackie
IJ
Porter
JB
Machin
SJ
Low plasma heparin cofactor II levels in thalassemia syndromes are corrected by chronic blood transfusion.
Br J Haematol.
90
1995
65
70
57
Middelkoop
E
Lubin
BH
Bevers
EM
et al
Studies on sickled erythrocytes provide evidence that the asymmetric distribution of phosphatidylserine in the red cell membrane is maintained by both ATP-dependent translocation and interaction with membrane skeletal proteins.
Biochim Biophys Acta.
937
1988
281
288
58
Tait
JF
Gibson
D
Measurement of membrane phospholipid asymmetry in normal and sickle cell erythrocytes by means of annexin V binding.
J Lab Clin Med.
123
1994
741
748
59
Barker
JE
Wandersee
NJ
Thrombosis in heritable hemolytic disorders.
Curr Opin Hematol.
6
1999
71
75
60
Borenstain-Ben Yashar
V
Barenholz
Y
Hy-Am
E
Rachmilewitz
EA
Eldor
A
Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes.
Am J Hematol.
44
1993
63
65
61
Helley
D
Eldor
A
Girot
R
Ducrocq
R
Guillin
MC
Bezeaud
A
Comparison of the procoagulant activity of red blood cells from patients with homozygous sickle cell disease and b-thalassemia.
Thromb Haemost.
76
1996
322
327
62
Kuypers
FA
Lewis
RA
Hua
M
et al
Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V.
Blood.
87
1996
1179
1184
63
Scheroit
AJ
Zwall
RFA
Transbilayer movement of phospholipids in red cell and platelet membranes.
Biochim Biophys Acta.
1071
1991
313
329
64
Zwaal
RFA
Comfurius
P
Bevers
EM
Mechanism and function of changes in membrane phospholipid asymmetry in platelets and erythrocytes.
Biochem Soc Trans.
21
1993
248
253
65
Connor
J
Pak
CC
Schroit
AJ
Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age and clearance by mononuclear cells.
J Biol Chem.
269
1994
2339
2345
66
Kuypers
FA
Yuan
J
Lewis
RA
et al
Membrane phospholipid asymmetry in human thalassemia.
Blood.
91
1998
3044
3048
67
Shinar
E
Rachmilewitz
EA
Hemoglobinopathies and red cell membrane function.
Baillieres Clin Haematol.
6
1993
357
369
68
Cappellini
MD
Tavazzi
D
Duca
L
et al
Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in beta-thalassemia intermedia.
Br J Haematol.
104
1999
504
512
69
Mannu
F
Arese
P
Cappellini
MD
et al
Role of hemichrome binding to erythrocyte membrane in the generation of band-3 alterations in beta-thalassemia intermedia erythrocytes.
Blood.
86
1995
2014
2020
70
Chen
S
Eldor
A
Barshtein
G
et al
Enhanced aggregability of red blood cells of beta-thalassemia major patients.
Am J Physiol.
270H
1996
1951
1956
71
Hassoun
H
Wang
Y
Mohini
VJ
et al
Targeted inactivation of murine band 3 (AE1) gene produces a hypercoagulable state causing widespread thrombosis in vivo.
Blood
92
1998
1785
1792
72
Kaysser
TM
Wandersee
NJ
Bronson
RT
Barke
JE
Thrombosis and secondary hemochromatosis play major roles in the pathogenesis of jaundiced and spherocytic mice, murine models for hereditary spherocytosis.
Blood
90
1997
4610
4619
73
Wandersee
NJ
Lee
JC
Deveau
SA
Barker
JE
Reduced incidence of thrombosis in mice with hereditary spherocytosis following neonatal treatment with normal hematopoietic cells.
Blood
97
2001
3972
3975
74
Foulon
I
Bachir
D
Galacteros
F
Maclouf
J
Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619.
Arterioscler Thromb.
13
1993
421
426
75
Peters
M
Plaat
BE
ten Cate
H
Wolters
HJ
Weening
RS
Brandjes
DP
Enhanced thrombin generation in children with sickle cell disease.
Thromb Haemost.
71
1994
169
172
76
Wolters
HJ
ten Cate
H
Thomas
LL
et al
Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?
Br J Haematol.
90
1995
715
717
77
Adams
RJ
Sickle cell disease and stroke.
J Child Neurol.
10
1995
75
76
78
Duncan
GW
Ischemic stroke in sickle cell disease: a review.
Tenn Med.
90
1997
498
499
79
Adams
RJ
Stroke prevention in sickle cell disease.
Curr Opin Hematol.
7
2000
101
105
80
Bernaudin
F
Verlhac
S
Freard
F
et al
Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation.
J Child Neurol.
15
2000
333
343
81
Kinney
TR
Sleeper
LA
Wang
WC
et al
Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease.
Pediatrics.
103
1999
640
645
82
Francis
RB
Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion.
Blood Coagul Fibrinolysis.
2
1991
341
353
83
Humphries
JE
Wheby
MS
Case report: sickle cell trait and recurrent deep venous thrombosis.
Am J Med Sci.
303
1992
112
114
84
Arnold
KE
Char
G
Serjeant
GR
Portal vein thrombosis in a child with homozygous sickle-cell disease.
West Indian Med J.
42
1993
27
28
85
Sheth
S
Ruzal-Shapiro
C
Hurlet-Jensen
A
Piomelli
S
Berdon
WE
Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy.
Pediatr Radiol.
27
1997
926
928
86
Koren
A
Zalman
L
Levin
C
Abu Hana
M
Mader
R
Shalev
S
Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Pediatr Hematol Oncol.
16
1999
469
472
87
El Hazmi
MAE
Warsy
AS
Bahakim
H
Blood protein C and S sickle cell disease.
Acta Haematol.
90
1993
114
117
88
Karayaclin
G
Lanzowsky
P
Plasma protein C levels in children with sickle cell disease.
Am J Pediatr Hematol Oncol.
11
1999
320
325
89
Tomer
A
Harker
LA
Kasey
S
Eckman
JR
Thrombogenesis in sickle cell disease.
J Lab Clin Med.
137
2001
398
407
90
Solovey
A
Lin
Y
Browne
P
Choong
S
Wayner
E
Hebbel
RP
Circulating activated endothelial cells in sickle cell anemia.
N Engl J Med.
337
1997
1584
1590
91
Solovey
A
Gui
L
Key
NS
Hebbel
RP
Tissue factor expression by endothelial cells in sickle cell anemia.
J Clin Invest.
101
1998
1899
1904
92
Adams
RJ
McKie
VC
Brambilla
D
et al
Stroke prevention trial in sickle cell anemia.
Control Clin Trials.
19
1998
110
129
93
Pegelow
CH
Adams
RJ
McKie
V
et al
Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions.
J Pediatr.
126
1995
896
899
94
Adams
RJ
McKie
VC
Hsu
L
et al
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.
N Engl J Med.
339
1998
5
11
95
Ryan
TM
Ciavatta
DJ
Townes
TM
Knockout-transgenic mouse model of sickle cell disease.
Science.
278
1997
873
876
96
Pászty
C
Brion
CM
Manci
E
et al
Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease.
Science.
278
1997
876
878
97
Jarva
H
Meri
S
Paroxysmal nocturnal hemoglobinuria: the disease and a hypothesis for a new treatment.
Scand J Immunol.
49
1999
119
125
98
Tomizuka
H
Hatake
K
Kitagawa
S
Yamashita
K
Arai
H
Miura
Y
Portal vein thrombosis in paroxysmal nocturnal hemoglobinuria.
Acta Haematol.
101
1999
149
152
99
Stewart
GW
Amess
JA
Eber
SW
et al
Thrombo-embolic disease after splenectomy for hereditary stomatocytosis.
Br J Haematol.
93
1996
303
310

Author notes

Eliezer A. Rachmilewitz, Department of Hematology, Edith Wolfson Medical Center, PO Box 5, Holon, Israel; e-mail:rachmilewitz@wolfson.health.gov.il.

Sign in via your Institution